Press Release

Vigilant Biosciences Announces New Website Launch  September 9, 2020  FORT LAUDERDALE, Fla., Sept. 9, 2020 /PRNewswire/ — Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection of oral and oropharyngeal cancer, is proud to announce the launch of its newly redesigned website at http://www.vigilantbiosciences.com/ . The new site features a streamlined, modern design, improved functionality, and easy access to

Vigilant Biosciences Names William Brodie as Chief Executive Officer August 7, 2018 FORT LAUDERDALE, Fla., Aug. 7, 2018 /PRNewswire/ — Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of oral and throat cancer, today announced the appointment of William “Bill” Brodie as Chief Executive Officer. Bill brings

Vigilant Biosciences Announces Grant Award from National Institutes of Health June 13, 2017 Fort Lauderdale, FLA. Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the that it has received an award as part of a multi-million dollar grant from the National

Vigilant Biosciences Announces Further Clinical Data in Support of its OncAlert™ Oral Cancer Product Line at IFOS ENT World Congress 2017 Symposium and at Annual MASCC Meeting June 21, 2017 Fort Lauderdale, Fla. and WASHINGTON and PARIS Company to exhibit as Bronze Sponsor of IFOS ENT World Congress and present interim analysis of European clinical

Vigilant Biosciences Announces Commencement of FDA Studies for OncAlert™ Cancer Test May 10, 2017 Company begins drive toward FDA clearance of first and only test to detect a tumor-initiating stem cell-associated biomarker for oral and oropharyngeal cancer Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention

Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups; Only 29 Percent Actually Are March 30, 2017 Fort Lauderdale, Fla. Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck

Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert™ Oral Cancer and OncAlert Labs Product Lines March 22, 2017 Fort Lauderdale, Fla. Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the acceptance of five abstracts regarding data related to studies

Vigilant Biosciences to Showcase OncAlert™ Oral Cancer Product Line at International Dental Show 2017 March 20, 2017 Fort Lauderdale, Fla. and Cologne, Germany OncAlert RAPID Test aids in the early detection and intervention of oral cancer; fits seamlessly into dental practice standard of care Vigilant Biosciences, Inc., a leading innovator and developer of solutions that

Vigilant Biosciences Announces Poster Presentation on Multivariate Oral Rinse Models for Prediction of Head and Neck Squamous Cell Carcinoma at the 6th International Conference on Innovative Approaches in Head and Neck Oncology March 15, 2017 Fort Lauderdale, Fla. and Barcelona, Spain Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the

Vigilant Biosciences to Present at Medtech Showcase 2017 and BioLink 2017 China Healthcare Industry Investment and Licensing Conference January 6, 2017 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that Matthew H.J. Kim, Founder, Chairman and Chief Executive Officer,